What is the recommended topical treatment regimen for an adult with mild-to-moderate plaque psoriasis?

Topical Treatment for Mild-to-Moderate Plaque Psoriasis

For adults with mild-to-moderate plaque psoriasis, initiate treatment with a combination product containing calcipotriene (vitamin D analogue) plus betamethasone dipropionate (potent corticosteroid), which is the most effective topical therapy available. 1

First-Line Treatment Algorithm

Initial Therapy (Weeks 1-4)

Combination calcipotriene/betamethasone dipropionate is recommended as first-line treatment 1:

• Apply once daily to affected areas
• Available as ointment, gel, or foam formulations
• Superior efficacy compared to either agent alone
• In 52-week studies, 69-74% of patients achieved clear or almost clear status 1

Alternative if combination unavailable:

• Class 2-5 topical corticosteroids (moderate to high potency) for body lesions 1
• Class 1 corticosteroids (ultrahigh potency) for thick, chronic plaques 1
• Apply for up to 4 weeks initially 1

Location-Specific Modifications

Scalp psoriasis:

• Calcipotriene foam OR calcipotriene/betamethasone dipropionate gel for 4-12 weeks 1
• Any potency corticosteroid (class 1-7) acceptable for scalp 1

Face and intertriginous areas:

• Tacrolimus 0.1% ointment (off-label) for up to 8 weeks 1
• Pimecrolimus (off-label) for inverse psoriasis 4-8 weeks 1
• Avoid high-potency corticosteroids due to atrophy risk 1

Nail psoriasis:

• Vitamin D analogues combined with betamethasone dipropionate 1

Maintenance Therapy (After Week 4)

Long-term management options (strength of recommendation A) 1:

1. Vitamin D analogues alone for up to 52 weeks 1

   • Calcipotriene, calcitriol, tacalcitol, or maxacalcitol
   • Safer for prolonged use than corticosteroids alone

2. Combination vitamin D/corticosteroid regimens:

   • Weekday/weekend split: Vitamin D analogues twice daily on weekdays + high-potency corticosteroids twice daily on weekends 1
   • Morning/evening split: High-potency corticosteroid in morning + vitamin D analogue in evening 1
   • Continuous combination product: Calcipotriene/betamethasone up to 52 weeks (no serious adverse events including striae or HPA axis suppression observed) 1

Additional Treatment Options

Tazarotene (topical retinoid):

• 0.05% or 0.1% cream/gel once daily for 8-12 weeks 1
• 40-51% treatment success rates 1
• Can combine with corticosteroids to reduce irritation

Adjunctive agents:

• Salicylic acid for thick plaques (8-16 weeks) 1
  • Critical caveat: Never use simultaneously with calcipotriene—the acidic pH inactivates calcipotriene 1
• Coal tar preparations for mild-to-moderate disease 1
• Anthralin 0.1% (short contact up to 2 hours daily) for 8-12 weeks 1

Key Safety Considerations

Corticosteroid adverse effects:

• Skin atrophy, striae, telangiectasia most common 1
• Face, intertriginous areas, and forearms at highest risk 1
• Rebound can occur with abrupt discontinuation 1
• Mitigation: Gradual tapering after improvement; consider steroid-sparing agents for maintenance 1

Calcineurin inhibitor warnings:

• FDA boxed warning for theoretical lymphoma risk (no evidence with topical use) 1
• Burning and pruritus common initially—improves with continued use 1
• Avoid application to moist skin to reduce irritation 1

Vitamin D analogue considerations:

• UVA radiation decreases calcipotriene concentration 1
• Apply after phototherapy if combining treatments 1

Treatment Targets and Monitoring

Therapeutic goals:

• Investigator's Static Global Assessment score of 0 (clear) or 1 (almost clear) 1
• Expect visible improvement by 4 weeks with corticosteroids 1
• Vitamin D analogues require 8 weeks for full efficacy 1

When to escalate:

• Inadequate response after 4-8 weeks of appropriate topical therapy
• Body surface area >10% affected
• High-impact areas (face, genitals, hands/feet) significantly affected
• Consider systemic therapy or phototherapy

Practical Application Tips

Dosing quantity:

• Apply approximately 1.0 g per 1% affected body surface area daily 2
• Increasing quantity improves outcomes in linear fashion 2
• Extended daily use up to 48 weeks provides progressive improvement 2

Vehicle selection:

• Ointments for thick, dry plaques
• Foams for scalp and hairy areas
• Gels for intertriginous areas
• Patient preference critical for adherence